Progyny, Inc.

PGNY

US74340E1038

Managed Healthcare

Real-time Estimate Cboe BZX Other stock markets 19:26:37 16/07/2024 BST			5-day change	1st Jan Change
29.93 ^USD	+3.10%		+6.50%	-19.34%

01:48pm	JMP Securities Initiates Progyny at Outperform With $36 Price Target	MT
07-01	Progyny, Inc.(NasdaqGS:PGNY) dropped from Russell 2000 Dynamic Index	CI

Progyny, Inc. Announces Appointment of Peter Anevski as Chief Financial Officer and Chief Operating Officer

January 09, 2017 at 01:00 pm

Progyny announced that the appointment of former WebMD CFO, Peter Anevski, as its Chief Financial Officer and Chief Operating Officer. Pete brings over 17 years of experience in the healthcare industry at WebMD.

Latest news about Progyny, Inc.

JMP Securities Initiates Progyny at Outperform With $36 Price Target	12:48pm	MT
Progyny, Inc.(NasdaqGS:PGNY) dropped from Russell 2000 Dynamic Index	06-30	CI
Progyny Acquires Germany's Apryl, Adds Fertility Benefits to Global Services	06-24	MT
Progyny, Inc. acquired Apryl GmbH.	06-23	CI
Transcript : Progyny, Inc. - Shareholder/Analyst Call	05-23
Progyny Gets Board Approval for $100 Million Share Repurchase Program; Stock Rises After Hours	05-22	MT
Progyny, Inc. announces an Equity Buyback for $100 million worth of its shares.	05-22	CI
Progyny, Inc. authorizes a Buyback Plan.	05-21	CI
Truist Securities Cuts Price Target on Progyny to $37 From $46, Keeps Buy Rating	05-17	MT
Transcript : Progyny, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 05:01 PM	05-16
Top Midday Decliners	05-10	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	05-10	MT
Progyny Shares Drop After Q1 Revenue Miss, KeyBanc Downgrade	05-10	MT
Tranche Update on Progyny, Inc.'s Equity Buyback Plan announced on February 29, 2024.	05-10	CI
Top Premarket Decliners	05-10	MT
KeyBanc Downgrades Progyny to Sector Weight From Overweight, Cites Questions on Visibility, 'Potential Further Headwinds'	05-10	MT
Progyny Q1 Adjusted Earnings, Revenue Rise -- Shares Plummet After Hour	05-09	MT
Transcript : Progyny, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
(PGNY) PROGYNY Forecasts Q2 EPS Range $0.39 - $0.41	05-09	MT
Earnings Flash (PGNY) PROGYNY Reports Q1 Revenue $278.1M, vs. Street Est of $289.1M	05-09	MT
Earnings Flash (PGNY) PROGYNY Reports Q1 EPS $0.39, vs. Street Est of $0.35	05-09	MT
Progyny, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024	05-09	CI
Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM	03-12
Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing	03-05	MT

Chart Progyny, Inc.

Duration

Period

More charts

Company Profile

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Sector

Managed Healthcare

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Progyny, Inc. : Want to have a baby?

October 16, 2023 at 06:55 pm

More Strategies

Ratings for Progyny, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.03 USD

Average target price

37.8 USD

Spread / Average Target

+30.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Managed Healthcare

	1st Jan change	Capi.
PROGYNY, INC.	-19.34%	2.76B
ELEVANCE HEALTH, INC.	+16.79%	123B
CIGNA	+13.63%	94.15B
HUMANA INC.	-13.46%	46.3B
CENTENE CORPORATION	-7.68%	35.22B
MOLINA HEALTHCARE, INC.	-16.33%	16.64B
ALIGNMENT HEALTHCARE, INC.	+14.63%	1.72B
CLOVER HEALTH INVESTMENTS, CORP.	+81.70%	784M

Other Managed Healthcare

Progyny, Inc.

Equities

PGNY

US74340E1038

Managed Healthcare

Progyny, Inc. Announces Appointment of Peter Anevski as Chief Financial Officer and Chief Operating Officer

EPS Revisions